ONO Pharmaceutical (OTCPK:OPHLY) to acquire all outstanding shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) for $25.60 per share in cash through a tender offer, resulting in an equity value of ...

Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday. The move serves to bolster Ono’s cancer pipeline, with oncology pinpointed ...

(Reuters) -Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 billion to expand its oncology portfolio and presence in the United States ...

ONO, as a Global Specialty Pharma company, is committed to delivering innovative new drugs to patients around the world. As a part of our medium-term management plan, ONO aims to reinforce our ...

Ono Pharmaceutical is expanding its scope in oncology with a $2.4 billion deal to buy Deciphera Pharmaceutical, a company that has one commercialized cancer therapy and a drug pipeline that includes a ...

Deciphera Pharmaceuticals, a Waltham cancer biotech, said Monday it will be bought by Ono Pharmaceutical for $2.4 billon to expand the Japanese firm’s oncology portfolio and spur its growth in the ...

Japan's Ono Pharmaceutical will buy kinase inhibitor expert Deciphera for $2.4 billion. Novartis invests further in radiopharmaceuticals with two deals. WuXi Biologics has withdrawn from the 2024 BIO ...

Deciphera Pharmaceuticals is being bought by ONO Pharmaceutical for $25.60 a share in cash through a tender offer with a total equity value of $2.4 billion. Deciphera shares are halted at $14.65 in ...

Deciphera Pharmaceuticals Inc. said Monday it has agreed to be acquired by Japan’s Ono Pharmaceutical Co. Ltd in an all-cash deal valued at $2.4 billion. Under the terms of the deal, Ono JP:4528 will ...

April 29 (Reuters) - Deciphera Pharmaceuticals (DCPH.O), opens new tab said on Monday Japan's Ono Pharmaceutical Co (4528.T), opens new tab will acquire the cancer drugmaker for $2.4 billion to expand ...